0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Latent TGF-beta 1

Latent TGF-beta 1

Brief Information

Name:Transforming growth factor beta 1
Target Synonym:TGFbeta,Transforming Growth Factor Beta 1,Diaphyseal Dysplasia 1, Progressive,TGF-Beta1,IBDIMDE,Transforming Growth Factor beta1,Latency-Associated Peptide,TGFB,CED,DPD1,Transforming Growth Factor, Beta 1,TGF-Beta-1,Prepro-Transforming Growth Factor Beta-
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

TG1-H524x-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human Latent TGFB1, His Tag (Cat. No. TG1-H524x) inhibits the IL-4-dependent proliferation of TF-1 cells. The ED50 for this effect is 0.293-0.406 ng/mL (Routinely tested).

TG1-C5243-ELISA
Cynomolgus Latent TGF-Beta 1 (C33S), His TagCynomolgus Latent TGF-Beta 1 (C33S), His Tag (Cat. No. TG1-C5243) ELISA bioactivity

Immobilized Cynomolgus Latent TGF-Beta 1 (C33S), His Tag (Cat. No. TG1-C5243) at 2 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-H82E4) with a linear range of 1-31 ng/mL (QC tested).

TG1-H524x-MALS-HPLC
Human Latent TGFB1, His Tag (Cat. No. ) MALS images

The purity of Human Latent TGFB1, His Tag(Cat. No. TG1-H524x) was more than 85% and the molecular weight of this protein is around 100-110 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human Latent TGFB1, His TagHuman Latent TGFB1, His Tag (Cat. No. TG1-H524x) ELISA bioactivity

Immobilized Human Latent TGFB1, His Tag (Cat. No. TG1-H524x) at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-H82E4) with a linear range of 1-20 ng/mL (QC tested).

Synonym Name

Latent TGF-beta 1,Latent TGFB1,TGFB1,CED,DPD1,LAP,TGF-beta-1,TGFB

Background

Transforming growth factor beta 1 ( TGFB1) is also known as TGF-β1, CED, DPD1, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis.  The TGFB1 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB1 protein is found throughout the body and plays a role in development before birth, the formation of blood vessels, the regulation of muscle tissue and body fat development, wound healing, and immune system function. TGFB1 is particularly abundant in tissues that make up the skeleton, where it helps regulate bone growth, and in the intricate lattice that forms in the spaces between cells (the extracellular matrix). Within cells, this protein is turned off (inactive) until it receives a chemical signal to become active. TGFB1 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages. Most immune cells (or leukocytes) secrete TGFB1. TGFB1 has been shown to interact with TGF beta receptor 1, LTBP1, YWHAE, EIF3I  and Decorin.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Pirfenidone F-647; AMR-69; GP-101; S-7701; S-770108; RO-0220912 Approved Intermune 艾思瑞, Deskar, Etuary, Esbriet, Pirespa, Aisuryui United States Idiopathic Pulmonary Fibrosis Genentech Inc 2008-10-16 Dermatomyositis; Radiation Pneumonitis; Renal Insufficiency; Idiopathic Pulmonary Fibrosis; Scleroderma, Systemic; Lung Diseases, Interstitial; Pulmonary Fibrosis; Diabetic Nephropathies; Pneumoconiosis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Nicousamide XLF-III-43 Phase 2 Clinical Institue Of Materia Medica Chinese Academy Of Medical Science Hypertensive nephropathy; Diabetic Nephropathies Details
Disitertide P-144; NAFB-001; Peptide-144 Phase 2 Clinical Digna Biotech, University Of Navarra Fibrosis; Scleroderma, Systemic Details
Vactosertib EW-7197; NOV-1301; TEW-7197 Phase 2 Clinical Medpacto Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Urologic Neoplasms; Colorectal Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
Fluorofenidone AKF-PD Phase 1 Clinical Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University Liver Cirrhosis; Renal fibrosis Details
YL-13027 YL-13027 Phase 1 Clinical Shanghai Yingli Pharmaceutical Co Ltd Solid tumours Details
Yinfenidone Hydrochloride HEC-585; HEC-00000585 Phase 2 Clinical Hec Pharm Co Ltd Idiopathic Pulmonary Fibrosis Details
DW-1029M DW-1029M Phase 2 Clinical Dong Wha Pharmaceuticals Diabetic Nephropathies Details
STP-705 STP-705L; STP-705LU; STP-705LV; STP-705 Phase 2 Clinical Suzhou Shengnuo Biological Medicine Technology Co Ltd, Sirnaomics Liver Neoplasms; Bowen's Disease; Carcinoma, Basal Cell; Cholangiocarcinoma; Carcinoma, Squamous Cell; Keloid; Cicatrix, Hypertrophic; Carcinoma, Hepatocellular Details
盐酸美氟尼酮 Phase 1 Clinical Guangzhou Nanxin Pharmaceutical Co Ltd, Central South University Diabetic Nephropathies Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop